If this file opens in Compatibility Mode using Microsoft Word, convert to the latest document format to avoid potential formatting issues.	

OP RESEARCH PRO00041696 / ABDELRAHIM RP2-003 COHORT 2 HEPATOCELLULAR CARCINOMA	

Types:      Research Oncology Treatment
Synonyms:  UNRESECTABLE, RECURRENT, METASTATIC

Week 1	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 4	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	An archival tumor specimen collected within 90 days (formalin-fixed paraffin embedded block or unstained slides) prior to the first dose of study treatment must be submitted to the central laboratory. If an archival tumor specimen collected within 90 days prior to the first dose of study treatment is not available, a fresh biopsy specimen can be collected on Week 1 Day 1 prior to first RP2 dosing on the same day. Biopsies should be taken from easily accessible tumors and, at the investigator's discretion, may be forgone if patient safety is deemed to be at unacceptable risk.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Whole blood must be collected and shipped on the day of collection. 
-  These samples may be collected up to 3 days before the visit to ensure delivery to the laboratory to allow for processing during normal business hours. 
-  Alternatively, the Sponsor may agree to selected centers processing whole blood locally. 
-  Instructions for each will be provided in a Laboratory Manual.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^6 PFU/mL LOW CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (LOW concentration). Administer intratumorally. Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
				Day 4 (Protocol Week 1 Day 4)	Perform every 1 day x1			Research tolerance: -0/+0 days	Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
					
Week 3	Repeat 1 time	Cycle length: 14 days	Day 1 ( Protocol Week 3 Day 15)	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Collect before RP2 dosing and only during the first course of RP2.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 2 weeks x 4 doses with no less than 12 days from previous dose.
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
				Day 4 (Protocol  Week 3 Day 18)	Perform every 1 day x1			Research tolerance: -0/+0 days	Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
					
Week 5	Repeat 1 time	Cycle length: 14 days	Day 1 (Protocol  Week 5 Day 29)	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	collect pre-dose
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Collect before RP2 dosing and only during the first course of RP2.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 2 weeks x 4 doses with no less than 12 days from previous dose.
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
				Day 4 (Protocol Week 5 Day 32)	Perform every 1 day x1			Research tolerance: -0/+0 days	Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
					
Week 7 Day 43	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Hepatitis B, Hepatitis C serology Information
-  Blood samples for HBsAg, HBcAb, and HBsAb should be collected during screening. 
-  HBV DNA must be collected during screening in patients who have negative serology for HBsAg and positive serology for anti HBc. 
-  Only if a patient tests positive for HBsAg, HBcAb, and/or anti-HCV at screening,  quantitative HBsAg, HBV DNA, and HCV RNA will need to be tested during screening and subsequently during Cycle 4 Day 1, Cycle 8 Day 1, and at  treatment discontinuation (end of treatment).
			Labs
  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --		  	HEPATITIS B SURFACE ANTIBODY	Interval: --	Occurrences: --			Labs
  	HEPATITIS C VIRUS (HCV) ANTIBODY WITH REFLEX TO PCR	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	As clinically indicated.
- Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. 
- Biopsies should be taken from easily accessible tumors and, at the investigator's discretion, may be forgone if patient safety is deemed to be at unacceptable risk. 
- On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. 
- Whole blood or biopsy samples may be collected up to 3 days prior to the protocol-specified day of collection to ensure delivery to the laboratory for processing during normal business hours. 
- Alternatively, the Sponsor may agree to selected centers processing whole blood locally. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Whole blood must be collected and shipped on the day of collection. 
-  These samples may be collected up to 3 days before the visit to ensure delivery to the laboratory to allow for processing during normal business hours. 
-  Alternatively, the Sponsor may agree to selected centers processing whole blood locally. 
-  Instructions for each will be provided in a Laboratory Manual.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Collect before RP2 dosing and only during the first course of RP2.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 2 weeks x 4 doses with no less than 12 days from previous dose.
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
					
Week 9 Day 57	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 3 weeks x 4 doses. 
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
				Day 8  (Protocol Week 10 Day 64)	Perform every 1 day x1			Research tolerance: -0/+0 days	Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
					
Week 11 Day 71	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 3 weeks x 4 doses. 
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
					
Week 13 Day 85	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 3 weeks x 4 doses. 
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
					
Week 15 Day 99	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Hepatitis B, Hepatitis C serology Information
-  Blood samples for HBsAg, HBcAb, and HBsAb should be collected during screening. 
-  HBV DNA must be collected during screening in patients who have negative serology for HBsAg and positive serology for anti HBc. 
-  Only if a patient tests positive for HBsAg, HBcAb, and/or anti-HCV at screening,  quantitative HBsAg, HBV DNA, and HCV RNA will need to be tested during screening and subsequently during Cycle 4 Day 1, Cycle 8 Day 1, and at  treatment discontinuation (end of treatment).
			Labs
  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --		  	HEPATITIS B SURFACE ANTIBODY	Interval: --	Occurrences: --			Labs
  	HEPATITIS C VIRUS (HCV) ANTIBODY WITH REFLEX TO PCR	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Whole blood must be collected and shipped on the day of collection. 
-  These samples may be collected up to 3 days before the visit to ensure delivery to the laboratory to allow for processing during normal business hours. 
-  Alternatively, the Sponsor may agree to selected centers processing whole blood locally. 
-  Instructions for each will be provided in a Laboratory Manual.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Line Care
  	INSERT PERIPHERAL IV OR ACCESS PORTACATH	Interval: --	Occurrences: --		  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Chemotherapy
  	INV-RP2 1x10^7 PFU/mL HIGH CONCENTRATION Syringe (RP2-003/Pro00039910/Abdelrahim)	Dose: --	Route: intratumoral	once for 1 dose	Start: S			Instructions:	Prepared syringe contains RP2 (HIGH concentration). Administer intratumorally. Dose volume determined by tumor size, max 10 mL per day. Given every 3 weeks x 4 doses. 
Stable at room temperature for 8 hours. 
HAZARDOUS - Handle with care
Caution: New Drug-Limited by Federal (USA) Law to Investigational use.			Hematology & Oncology Hypersensitivity Reaction Standing Order
  	ONC NURSING COMMUNICATION 82	Interval: --	Occurrences: --	Comments:	Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only - itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 4	Interval: --	Occurrences: --	Comments:	Grade 2 - MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms - shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Cetirizine 10 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	ONC NURSING COMMUNICATION 83	Interval: --	Occurrences: --	Comments:	Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)
1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.
		  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S				  	cetirizine (ZyrTEC) tablet 10 mg	Dose: 10 mg	Route: oral	once PRN	Start: S				  	famotidine (PEPCID) injection 20 mg	Dose: 20 mg	Route: intravenous	PRN	Start: S				  	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	Dose: 100 mg	Route: intravenous	PRN					  	dexAMETHasone (DECADRON) IV 4 mg	Dose: 4 mg	Route: intravenous	PRN					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled			Discharge Nursing Orders
  	ONC NURSING COMMUNICATION 76	Interval: --	Occurrences: --	Comments:	Discontinue IV.
					
Week 17 Day 113	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 19 Day 127	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 21 Day 141	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 23 Day 155	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 25 Day 169	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 27 Day 183	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 29 Day 197	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 31 Day 211	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
					
Week 33 Day 225	Repeat 1 time	Cycle length: 14 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Appointment Requests
  	ONC INFUSION APPOINTMENT REQUEST 6	Interval: --	Occurrences: --			Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Central and local laboratory assessments for enrollment and dosing decision.
			Labs
  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Labs may be done up to 3 days prior to dosing
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
					
End of Treatment	Repeat 1 time	Cycle length: 30 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Hepatitis B, Hepatitis C serology Information
-  Blood samples for HBsAg, HBcAb, and HBsAb should be collected during screening. 
-  HBV DNA must be collected during screening in patients who have negative serology for HBsAg and positive serology for anti HBc. 
-  Only if a patient tests positive for HBsAg, HBcAb, and/or anti-HCV at screening,  quantitative HBsAg, HBV DNA, and HCV RNA will need to be tested during screening and subsequently during Cycle 4 Day 1, Cycle 8 Day 1, and at  treatment discontinuation (end of treatment).
			Labs
  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --		  	HEPATITIS B SURFACE ANTIBODY	Interval: --	Occurrences: --			Labs
  	HEPATITIS C VIRUS (HCV) ANTIBODY WITH REFLEX TO PCR	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Amylase, lipase (central laboratory)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  To be collected when CRS is suspected.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
					
30-Day Follow Up	Repeat 1 time	Cycle length: 30 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
					
60-Day Follow Up	Repeat 1 time	Cycle length: 75 days	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Symptom-directed Physical examination
-  Includes height (at Screening only) and weight (at any time point described).
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	ECOG performance status
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Close contact questions
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Prior and concomitant medications
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	-  Vital signs include sitting blood pressure, resting pulse, respiratory rate, body temperature, and pulse oximetry at screening and whenever clinically indicated.
		  	MEASURE WEIGHT	Interval: --	Occurrences: --		  	ECG 12-LEAD	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Local laboratory results will be used at Screening for eligibility at times when/if central laboratory results are unable to be obtained in time. Local laboratory testing before dosing may be used for treatment decisions or for acute patient management. Labs may be done up to 3 days prior to dosing.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --			Labs
  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	Pregnancy Tests
-  A serum hCG pregnancy test will be performed for all women of child-bearing potential at screening LESS than or EQUAL 72 hours before the first study treatment. 
-  A urine pregnancy test will also be performed for all women of child-bearing potential at all other specified time points, including before administration of study treatment. 
-  If the urine test at any time point is positive, a serum pregnancy test will be done by the local laboratory for confirmation.
			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --	Comments:	For women of child-bearing potential.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Chemistry, hematology, coagulation (central laboratory)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Blood and urine for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Saliva/oral mucosa swab for RP2 detection (biodistribution)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RP2 injection site/dosing swab for RP2 detection (bioshedding)
		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Sample for HSV-1/herpetic-like infection. AS CLINICALLY INDICATED.
			Outpatient Electrolyte Replacement Protocol
  	TREATMENT CONDITIONS 39	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Potassium level LESS than 3.5 mEq/L; 
3. Recent pre-infusion labs.   

Dosing is based on lab value.
o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP. 
o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO. 
o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO. 
o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
		  	TREATMENT CONDITIONS 40 	Interval: --	Occurrences: --	Comments:	The protocol applies only if the following is met. 
1. SCr LESS than 1.5; 
2. Magnesium level LESS than 1.6 mg/dL; 
3. Recent pre-infusion labs. 

Dosing is based on lab value. 
o Serum Magnesium less than 1.0 mg/dL, give 2 gram magnesium sulfate IV and contact MD/NP. 
o Serum Magnesium 1.0 to 1.2 mg/dL, give 2 gram magnesium sulfate IV. 
o Serum Magnesium 1.3 to 1.5 mg/dL, give 1 gram magnesium sulfate IV. 
o Serum Magnesium 1.6 mg/dL or greater, do not give magnesium replacement. 

If patient meets criteria, order THERAPY PLAN called "Outpatient Electrolyte Replacement". 
Sign electrolyte replacement order as Per protocol: cosign required.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	-  Blood samples for plasma are collected at Screening, during Week 1 (Day 1 (pre dose), Day 2, and Day 3), Week 3 (Day 15 (pre dose), Day 16 and Day 17) and at pre dose during Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, and end of treatment. 
-  Blood samples should be collected at disease progression, complete response
-  Please refer to Laboratory Manual for additional instructions.
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Recommended biopsies, optimally of both injected and noninjected tumors, may be collected at Week 7 Day 43 for on treatment biopsy and if the Investigator believes a lesion has regressed due to necrosis and/or may have become free of viable tumor, and/or upon PD and/or EOT. Biopsies should be taken from easily accessible tumors and at the investigator's discretion may be forgone if patient safety is deemed to be at unacceptable risk. On days when a biopsy(ies) is (are) collected, whole blood should also be taken for biomarker analyses. Whole blood or biopsy samples may be collected up to 3 days prior to the protocol specified day of collection to ensure delivery to the laboratory for processing during normal business hours. Please refer to the Laboratory Manual for specific instructions
			Imaging
  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Imaging and Tumor Assessments
- Must include chest, abdomen, pelvis as well as any other areas of disease at both screening and follow-up. 
- When using CT, all abdominal CTs must be 3 or 4 phase. A radiographic scan and assessment should be performed at least 4 to 8 weeks from initial Investigator assessed progression to determine whether there has been continued progressive disease (refer to Appendix E and Appendix F for imaging and assessment guidelines). 
- A biopsy may be used to confirm the response status of individual lesions. The same imaging modality that was used for a patient's baseline assessment must be used throughout the study.
		  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	Or MRI
		  	MRI CHEST W CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI ABDOMEN W WO CONTRAST	Interval: --	Occurrences: --	Comments:	Or CT
		  	MRI PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --	Comments:	Or CT
					
Survival Follow-Up Period	Repeat 1 time	Cycle length: 1 day	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Nursing: Protocol Hyperlink: 
-  Please refer to Study Protocol for any questions or discrepancies. 
-  See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration.
-  See Safety Parameters-for Toxicity Management and Dose Modification Guidelines.
			Nursing Orders
  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Survival Status
-  Patients will be followed for survival approximately every 3 months over the phone for up to 3 years from their first RP2 dose or until death, withdrawal of consent, or loss to follow-up, whichever occurs first.
-  During the survival follow-up period, record Adverse Events (AEs) and Serious Adverse Events (SAEs) deemed related to RP2; and any new malignancy(ies), neurologic disorder, autoimmune disorder, hematologic disorder, and herpes or herpetic-like infections, regardless of causality, every 3 months. 
-  Record symptoms and dates symptoms were present, if appropriate, and dates of new diagnoses. 
-  Record medications and treatments the patient is receiving or has received. 
-  For herpes or herpetic-like infections, record symptoms and dates symptoms were present every 3 months. Any time a patient reports a suspected herpetic-like infection, they should return to the clinic for a biological sample (eg, swab) to be collected from the affected area(s). These samples should be obtained as soon as possible after symptoms arise to maximize the possibility of detection of the virus, optimally within 24 hours, but samples may be collected later if collection within 
24 hours is not possible.
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	AESIs (HSV-1/herpetic-like infection) will be collected from first dose of study treatment through end of study.
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Adverse Event (AE) / Serious Adverse Event (SAE) review